Fast approaching the end of its patent life, Roche and Novartis’ Xolair is going out with a bang, picking up a new approval as the first and only drug therapy for people with food allergies in ...

Joshua Cohen is a Boston-based writer who covers health policy. Two weeks ago, the Food and Drug Administration approved Xolair (omalizumab) for immunoglobulin E-mediated food allergy in certain ...

That hope now look decidedly faint, as ligelizumab was able to match Xolair (omalizumab) but not improve on it in a pair of phase 3 trials in CSU, although it did perform better than placebo.